DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli
- PMID: 1855210
DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli
Abstract
In the absence of excision repair, doxorubicin caused a striking (41-fold) increase in the frequency of large deletion mutations extending from the lac operator (lacO) into the lac repressor gene (lacI) of Escherichia coli. In contrast, there was only a 2-fold increase in the frequency of small deletions despite a 3-fold increase in overall mutation frequency. The 5'-endpoints of doxorubicin-induced lacO and lacI/lacO deletions occurred at the DNA sequence 5'-pyTAA or 5'-AATpy (where py is pyrmidine) (16%), at runs of purines or pyrimidines (41%) and adjacent to 5'-dGdC or 5'-dCdG doublets (34%). Ninety % (27 of 30) of the doxorubicin-induced deletions involving the region of the lacO palindrome had 3'-endpoints within the palindrome sequence as compared with 40% (4 of 10) spontaneous deletions in an untreated set. Doxorubicin-induced single base substitutions were highly focused at one site (4 of 6) in the i-d region of lacI, in contrast to the spontaneous distribution of point mutations, where 16 mutants were recovered at 12 different sites. An increased frequency (3-fold) of highly focused base substitutions was also observed at 2 sites in the lac operator region (at lacO +6, which is a transition "hotspot" in the spontaneous spectra of both wild type and uvrB- organisms and at the adjacent +5 site). Notably, the frequency of 1- and 2-base frameshifts did not increase in the doxorubicin-induced spectrum, relative to the spontaneous mutation spectrum. These in vivo observations in E. coli suggest that in the absence of excision repair, doxorubicin causes highly focused deletions and base substitutions. These mutations occur adjacent to DNA sequences identified in previous in vitro studies as preferential sites of doxorubicin binding.
Similar articles
-
Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli.Environ Mol Mutagen. 1995;26(1):16-25. doi: 10.1002/em.2850260104. Environ Mol Mutagen. 1995. PMID: 7641704
-
Escherichia coli mutator (Delta)polA is defective in base mismatch correction: the nature of in vivo DNA replication errors.J Mol Biol. 2005 Aug 12;351(2):299-308. doi: 10.1016/j.jmb.2005.06.014. J Mol Biol. 2005. PMID: 16005896
-
Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.Mutat Res. 1995 Jan;326(1):17-27. doi: 10.1016/0027-5107(94)00155-x. Mutat Res. 1995. PMID: 7528882
-
Influence of DNA repair on mutation spectra in Salmonella.Mutat Res. 2000 May 30;450(1-2):5-17. doi: 10.1016/s0027-5107(00)00013-0. Mutat Res. 2000. PMID: 10838131 Review.
-
Study of mutational specificity in the lacl gene of Escherichia coli as a window on the mechanisms of mutation.Environ Mol Mutagen. 1990;16(1):48-54. doi: 10.1002/em.2850160109. Environ Mol Mutagen. 1990. PMID: 2197087 Review.
Cited by
-
Anthracycline antibiotics in cancer therapy. Focus on drug resistance.Drugs. 1994 Feb;47(2):223-58. doi: 10.2165/00003495-199447020-00002. Drugs. 1994. PMID: 7512899 Review.
-
Advances in delivery systems for doxorubicin.J Nanomed Nanotechnol. 2018;9(5):519. doi: 10.4172/2157-7439.1000519. Epub 2018 Nov 4. J Nanomed Nanotechnol. 2018. PMID: 30613436 Free PMC article.
-
Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.Biochem Biophys Res Commun. 2019 May 21;513(1):242-247. doi: 10.1016/j.bbrc.2019.03.190. Epub 2019 Apr 4. Biochem Biophys Res Commun. 2019. PMID: 30954222 Free PMC article.
-
pH-Dependent Non-Covalent Release of Chemotherapy from Carriers.Discov Med. 2024 Mar;36(182):448-456. doi: 10.24976/Discov.Med.202436182.42. Discov Med. 2024. PMID: 38531786 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous